# Anti-Epilepsy Medication Valproate Administered Via ICV Route and Catheters and Pumps for CSF Infusion

> **NCT04529954** · PHASE1,PHASE2 · TERMINATED · sponsor: **Cerebral Therapeutics LLC** · enrollment: 20 (actual)

## Conditions studied

- Focal Epilepsy

## Interventions

- **DRUG:** Valproic Acid delivered to ICV

## Key facts

- **NCT ID:** NCT04529954
- **Lead sponsor:** Cerebral Therapeutics LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-01-01
- **Primary completion:** 2024-03-01
- **Final completion:** 2024-03-01
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Company Decision
- **Last updated:** 2024-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04529954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04529954, "Anti-Epilepsy Medication Valproate Administered Via ICV Route and Catheters and Pumps for CSF Infusion". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04529954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*